Accordingly, dasatinib (SRC inhibitor) and erlotinib (EGFR inhibitor) treatment reduces pancreatic cancer cell migration and invasion, overcomes STAT3-mediated chemoresistance, and attenuates the growth of PDAC xenografts [79]. This evidence concerns the gene STAT3 and familial pancreatic carcinoma.